Osimertinib Has Transformed Lung Cancer Care — But at What Cost to the Heart?
Muhammad Awidi, Hematology and Oncology Fellow at Roswell Park Cancer Center, shared on LinkedIn.
”Osimertinib has changed the landscape for EGFR-mutated lung cancer, but its long-term heart safety has remained uncertain.
In our latest paper, we found that patients treated with osimertinib had higher rates of cardiomyopathy, ischemic heart disease, and heart failure compared with earlier-generation EGFR inhibitors. As survival improves, our findings highlight the need for ongoing cardiovascular monitoring to help prevent late toxicities.
Grateful to my outstanding co-authors Zaid Muhanna, Muntaser Zyoud, and Ahmad Issa three talented medical students I had the privilege to mentor on this project.”
Read the full Abstract here.
Stay updated with Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders